| |
|
|
Acorda (NASDAQ: ACOR)
Acorda develops therapeutic products for spinal cord injury and other central nervous system disorders.
(IPO February 2006)
www.acorda.com
|
|
| |
|
|
Anesiva (NASDAQ: ANSV)
Anesiva develops innovative drugs for the treatment
of acute and chronic pain.
(Originally AlgoRx, merger w/ Corgentech in December 2005.)
www.anesiva.com |
|
| |
|
|
Athenix
Athenix develops and commercializes high-value genetic
traits from microbes for use in agricultural products.
(Acquired by Bayer Crop Sciences in November 2009.)
www.athenixcorp.com
|
|
| |
|
|
Avalon
Avalon discovers and develops novel drugs for various cancers. (Merged w/ Clinical Data Inc in May '09 – NSDQ:CLDA)
www.avalonrx.com
|
|
| |
 |
|
BioMs (TSX: MS)
BioMs develops unique biologics for autoimmune
diseases with a special emphasis on multiple sclerosis.
www.biomsmedical.com
|
|
| |
|
|
InteKrin
InteKrin Therapeutics in-licenses and develops drugs for the treatment of various metabolic diseases.
www.intekrin.com
|
|
| |
|
|
IntelliDx
IntelliDx is developing an automated, bedside blood analyzer for use in the critical care areas of hospitals.
www.intellidx.com
|
|
| |
 |
|
MacroGenics
MacroGenics is focused on the development of improved
immunotherapeutic products and the identification of
new targets for the treatment of cancer, autoimmune disorders, allergy, or infectious
diseases.
www.macrogenics.com
|
|
| |
 |
|
Morphotek
Morphotek develops therapeutic monoclonal antibodies
for the treatment of cancer, inflammatory and infectious
diseases. (Acquired by Eisai Pharmaceuticals in April 2007.)
www.morphotek.com
|
|
| |
 |
|
Myogen
Myogen is engaged in the discovery and development of
drugs for the treatment of heart failure and related
cardiovascular conditions.
(IPO 2003; acquired by Gilead Sciences in 2006.)
www.myogen.com
|
|
| |
 |
|
Novelos (OTC BB: NVLT)
Novelos develops oxidized glutathione-based drugs
for the treatment of cancer and hepatitis.
www.novelos.com
|
|
| |
 |
|
Peptimmune
Peptimmune develops drugs for the treatment of various
autoimmune diseases.
www.peptimmune.com
|
|
| |
 |
|
Salmedix
Salmedix develops oncology drugs with an initial
emphasis on hematologic cancers.
(Acquired by Cephalon in 2005.)
www.cephalon.com
|
|
| |
 |
|
Sirtris
Sirtris develops novel treatments for metabolic
disease
with a focus on sirtuin enzymology. (IPO 2007; acquired by GSK in April 2008.)
www.sirtrispharma.com
|
|
| |
 |
|
Synageva
Synageva develops novel, next-generation and follow-on protein therapeutics that leverage the unique competitive advantages of its expression platform.
www.synageva.com
|
|
